^
Association details:
| Biomarker: | FOXP1 overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Brukinsa (zanubrutinib) (BTK inhibitor) |
| Drug Class: | CD20 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BIOMARKER IDENTIFICATION IN RELAPSED/REFRACTORY NON-GERMINAL CENTER B-CELL–LIKE DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ZANUBRUTINIB
Published date:
06/27/2020
Excerpt:
For the 56 non-GCB patients with HTG gene expression profiles, PAX5 expression was significantly higher in monotherapy responders, and PIM1, BCL2, and FOXP1 expression was higher in combination therapy responders.
